HK1214165A1 - 特定構象抗體生成和使用的方法和組合物 - Google Patents

特定構象抗體生成和使用的方法和組合物

Info

Publication number
HK1214165A1
HK1214165A1 HK16102295.0A HK16102295A HK1214165A1 HK 1214165 A1 HK1214165 A1 HK 1214165A1 HK 16102295 A HK16102295 A HK 16102295A HK 1214165 A1 HK1214165 A1 HK 1214165A1
Authority
HK
Hong Kong
Prior art keywords
conformation
bodies
compositions
generation
methods
Prior art date
Application number
HK16102295.0A
Other languages
English (en)
Inventor
Kun Ping Lu
Xiao Zhen Zhou
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of HK1214165A1 publication Critical patent/HK1214165A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16102295.0A 2013-03-15 2016-02-26 特定構象抗體生成和使用的方法和組合物 HK1214165A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792588P 2013-03-15 2013-03-15
PCT/US2014/027017 WO2014152157A2 (en) 2013-03-15 2014-03-14 Methods and compositions for the generation and use of conformation-specific antibodies

Publications (1)

Publication Number Publication Date
HK1214165A1 true HK1214165A1 (zh) 2016-07-22

Family

ID=51581680

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102295.0A HK1214165A1 (zh) 2013-03-15 2016-02-26 特定構象抗體生成和使用的方法和組合物

Country Status (9)

Country Link
US (1) US9688747B2 (zh)
EP (1) EP2968548B1 (zh)
JP (1) JP6448614B2 (zh)
CN (1) CN105283196B (zh)
AU (1) AU2014240063B2 (zh)
CA (1) CA2903091C (zh)
ES (1) ES2835716T3 (zh)
HK (1) HK1214165A1 (zh)
WO (1) WO2014152157A2 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10351914B2 (en) 2014-07-17 2019-07-16 Beth Israel Deaconess Medical Center, Inc. Biomarkers for Pin1-associated disorders
TWI669314B (zh) * 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US20200079825A1 (en) * 2015-07-13 2020-03-12 The General Hostital Corporation Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
MX2018010948A (es) 2016-03-11 2019-06-20 Scholar Rock Inc INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
MY197413A (en) * 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
CN111587123A (zh) * 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
WO2019175735A1 (en) * 2018-03-11 2019-09-19 Koorosh Shahpasand Conformation-independent antibodies against neurotoxic tau proteins
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
CN112979797B (zh) * 2021-04-28 2022-04-01 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体及其制备方法与应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
EP1013270A3 (en) 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
ATE197398T1 (de) 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
SK281571B6 (sk) 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6462173B1 (en) 1997-09-08 2002-10-08 Max-Planck-Gesellschaft Zur Forderung Der Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases
US6441140B1 (en) 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
EP1476120B1 (en) * 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
US7161060B1 (en) * 2002-07-16 2007-01-09 Albert Einstein College Of Medicine Of Yeshiva University Transgenic mice comprising a genomic human tau transgene
EP1484336A1 (en) 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
US20080058276A1 (en) 2006-01-13 2008-03-06 Cornell Research Foundation, Inc. Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein
EP2035454A2 (en) 2006-05-19 2009-03-18 Amgen, Inc. Antibodies to sars coronavirus
EP2210939A4 (en) * 2007-10-16 2012-08-08 Sbi Biotech Co Ltd ANTIBODY ANTI-BST2
EP2210901A4 (en) * 2007-10-19 2012-04-25 Immunas Pharma Inc ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO OLIGOMER A, AND USE THEREOF
MX2012003811A (es) 2009-10-02 2012-05-08 Univ California Anticuerpos monoclonales.
US8771693B2 (en) * 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies

Also Published As

Publication number Publication date
JP2016515129A (ja) 2016-05-26
US20160031977A1 (en) 2016-02-04
WO2014152157A3 (en) 2014-12-24
WO2014152157A2 (en) 2014-09-25
EP2968548A4 (en) 2016-11-30
CN105283196A (zh) 2016-01-27
CN105283196B (zh) 2018-10-12
EP2968548A2 (en) 2016-01-20
WO2014152157A8 (en) 2015-09-17
ES2835716T3 (es) 2021-06-23
JP6448614B2 (ja) 2019-01-09
CA2903091C (en) 2022-09-06
CA2903091A1 (en) 2014-09-25
EP2968548B1 (en) 2020-09-09
AU2014240063A1 (en) 2015-09-17
US9688747B2 (en) 2017-06-27
AU2014240063B2 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
HK1214165A1 (zh) 特定構象抗體生成和使用的方法和組合物
IL289821B (en) Preparations and methods for immunotherapy
HK1220387A1 (zh) 用於免疫療法的組合物和方法
EP3008170A4 (en) SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
HK1211866A1 (zh) 抗氧化劑組合物及其使用方法
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
IL265876A (en) Preparations that include 15-ohepa and methods of using them
IL285527A (en) Preparations and methods for immunotherapy
HUE046723T2 (hu) Töltõanyag-készítmény lipoatrófia kezelésére
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same